Nerve conduction studies are often used as a simple noninvasive follow-up test, but findings should be interpreted with clinical judgment because of the variability inherent in these tests.
It is yet unclear whether the approaches used to diagnose CIDP are also appropriate methods of monitoring response to therapy. For example, nerve ultrasound and MRI are useful in diagnosis, but their sensitivity in monitoring has not been validated.
Improvement of conduction velocities without significant recovery of the size of motor potentials typically does not relay important clinical information because it is often operator-dependent.
Whether changes in antibody levels after treatment may serve as a surrogate for the effectiveness of therapy is not yet clear; however, this approach would be feasible only in subsets of patients with CIDP.
Although clinical criteria for diagnosis and monitoring of CIDP subtypes have not yet been defined, they are expected to be included in the second revision of the CIDP guidelines from the European Federation of Neurological Societies/Peripheral Nerve Society.
Learn more about follow-up in CIDP.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Jafar Kafaie. Fast Five Quiz: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Management - Medscape - Jun 24, 2021.